
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 19 |
| Herbal medicine | 2 |
| Gene therapy | 1 |
| Therapeutic vaccine | 1 |
| Polypeptide antibiotic | 1 |
Target |
Mechanism TRIM33 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism cysteine protease inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PTP1B inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Feb 2026 |
Sponsor / Collaborator |
Start Date04 Nov 2025 |
Sponsor / Collaborator |
Start Date01 Oct 2025 |
Sponsor / Collaborator |


| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Dihydroflavonol compound 4(Gyeongsang National University) ( PTP1B ) | Obesity More | Preclinical |
Flavone compound 8(Gyeongsang National University) ( PTP1B ) | Obesity More | Preclinical |
Flavone compound 9(Gyeongsang National University) ( PTP1B ) | Obesity More | Preclinical |
COM63 ( PTP1B ) | Obesity More | Preclinical |
Flavone compound 7(Gyeongsang National University) ( PTP1B ) | Obesity More | Preclinical |





